1222 related articles for article (PubMed ID: 29957821)
1. Immunosuppressive treatment for proliferative lupus nephritis.
Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
[TBL] [Abstract][Full Text] [Related]
2. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
4. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
[TBL] [Abstract][Full Text] [Related]
5. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
6. Interventions for minimal change disease in adults with nephrotic syndrome.
Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
8. Interventions for renal vasculitis in adults.
Walters GD; Willis NS; Cooper TE; Craig JC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD003232. PubMed ID: 31927782
[TBL] [Abstract][Full Text] [Related]
9. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
[TBL] [Abstract][Full Text] [Related]
10. Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM; Sinha A; Cooper TE
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732
[TBL] [Abstract][Full Text] [Related]
11. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM; Wong SC; Willis NS; Craig JC
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing and treating kidney disease in IgA vasculitis.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD005128. PubMed ID: 36853224
[TBL] [Abstract][Full Text] [Related]
13. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials.
Palmer SC; Tunnicliffe DJ; Singh-Grewal D; Mavridis D; Tonelli M; Johnson DW; Craig JC; Tong A; Strippoli GFM
Am J Kidney Dis; 2017 Sep; 70(3):324-336. PubMed ID: 28233655
[TBL] [Abstract][Full Text] [Related]
14. Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ; Reid S; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD003962. PubMed ID: 38299639
[TBL] [Abstract][Full Text] [Related]
15. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
16. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
18. Treatment for lupus nephritis.
Flanc RS; Roberts MA; Strippoli GF; Chadban SJ; Kerr PG; Atkins RC
Cochrane Database Syst Rev; 2004; (1):CD002922. PubMed ID: 14973998
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
20. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
